{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:43:34Z","timestamp":1793371414325,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007338","name":"All-India Institute of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.seizure.2024.08.003","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T12:17:58Z","timestamp":1722687478000},"page":"123-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Is there any concern of insulin resistance and metabolic dysfunctions with antiseizure medications? A prospective comparative study of valproate vs. levetiracetam"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3587-0968","authenticated-orcid":false,"given":"Sudhir Chandra","family":"Sarangi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya Sucharita","family":"Pattnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajnaseni","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjari","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Velpandian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2024.08.003_bib0001","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1600-0404.2010.01372.x","article-title":"Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine","volume":"190","author":"Svalheim","year":"2010","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.seizure.2024.08.003_bib0002","doi-asserted-by":"crossref","unstructured":"Li C.C., Chang C.C., Cherng Y.G., Lin C.S., Yeh C.C., Chang Y.C., et al. Risk and outcomes of diabetes in patients with epilepsy. Sci Rep. 2021;11(1):18888. doi: 10.1038\/s41598-021-98340-x. PMID: 34556733; PMCID: PMC8460720.","DOI":"10.1038\/s41598-021-98340-x"},{"issue":"4","key":"10.1016\/j.seizure.2024.08.003_bib0003","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4103\/ijp.IJP_507_17","article-title":"Prescription pattern of antiepileptic drugs in a tertiary care center of India","volume":"52","author":"Joshi","year":"2020","journal-title":"Indian J Pharmacol"},{"issue":"3","key":"10.1016\/j.seizure.2024.08.003_bib0004","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4103\/0971-5916.182623","article-title":"Comparison of body composition in persons with epilepsy on conventional & new antiepileptic drugs","volume":"143","author":"Sarangi","year":"2016","journal-title":"Indian J Med Res"},{"issue":"5","key":"10.1016\/j.seizure.2024.08.003_bib0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eplepsyres.2014.01.014","article-title":"Effect of antiepileptic therapy on trace elements status in Indian population in a tertiary care hospital from northern India: a cross sectional study","volume":"108","author":"Sarangi","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2024.08.003_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2017.03.007","article-title":"Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: a prospective study","volume":"48","author":"Sidhu","year":"2017","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.seizure.2024.08.003_bib0007","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1586\/17512433.2015.991716","article-title":"Antiepileptic drugs influences on body weight in people with epilepsy","volume":"8","author":"Hamed","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2\u20133","key":"10.1016\/j.seizure.2024.08.003_bib0008","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eplepsyres.2008.03.017","article-title":"Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children","volume":"80","author":"Rauchenzauner","year":"2008","journal-title":"Epilepsy Res"},{"issue":"5","key":"10.1016\/j.seizure.2024.08.003_bib0009","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1046\/j.1528-1157.2002.31501.x","article-title":"Serum insulin and leptin levels in valproate-associated obesity","volume":"43","author":"Pylv\u00e4nen","year":"2002","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2024.08.003_bib0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/en.2005-1030","article-title":"Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid","volume":"147","author":"Qiao","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.seizure.2024.08.003_bib0011","doi-asserted-by":"crossref","unstructured":"Contreras-Garc\u00eda I.J., C\u00e1rdenas-Rodr\u00edguez N., Romo-Mancillas A., Bandala C., Zamudio S.R., G\u00f3mez-Manzo S., et al. Levetiracetam mechanisms of action: from molecules to systems. Pharmaceuticals (Basel). 2022;15(4):475. doi: 10.3390\/ph15040475. PMID: 35455472; PMCID: PMC9030752.","DOI":"10.3390\/ph15040475"},{"issue":"1","key":"10.1016\/j.seizure.2024.08.003_bib0012","first-page":"3","article-title":"Do antiepileptics have any potential to induce insulin resistance? A comparison between levetiracetam and valproic acid","volume":"5","author":"G\u00f6khan","year":"2019","journal-title":"Eur Res J"},{"issue":"2","key":"10.1016\/j.seizure.2024.08.003_bib0013","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1528-1167.2007.01273.x","article-title":"Dramatic weight loss with levetiracetam","volume":"49","author":"Gelisse","year":"2008","journal-title":"Epilepsia"},{"issue":"7420","key":"10.1016\/j.seizure.2024.08.003_bib0014","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/bmj.327.7420.905","article-title":"Drug points: weight loss associated with levetiracetam","volume":"327","author":"Hadjikoutis","year":"2003","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.seizure.2024.08.003_bib0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/jnnp-2012-303688","article-title":"Weight change associated with antiepileptic drugs","volume":"84","author":"Pickrell","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.seizure.2024.08.003_bib0016","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s11940-010-0080-y","article-title":"Antiepileptic drugs and markers of vascular risk","volume":"12","author":"Lopinto-Khoury","year":"2010","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.seizure.2024.08.003_bib0017","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.eplepsyres.2017.10.016","article-title":"Evaluate the effects of antiepileptic drugs on reproductive endocrine system in newly diagnosed female epileptic patients receiving either Valproate or Lamotrigine monotherapy: a prospective study","volume":"139","author":"Sidhu","year":"2018","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.seizure.2024.08.003_bib0018","first-page":"2","article-title":"New adipocytokines (vaspin, apelin, visfatin, adiponectin) levels in children treated with valproic acid","volume":"22","author":"Meral","year":"2011","journal-title":"Eur Cytokine Netw"},{"issue":"4","key":"10.1016\/j.seizure.2024.08.003_bib0019","first-page":"1","article-title":"A study of insulin resistance by HOMA-IR and its cut-off value to identify metabolic syndrome in urban Indian adolescents","volume":"5","author":"Singh","year":"2013","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"10.1016\/j.seizure.2024.08.003_bib0020","series-title":"World health organization. the asia pacific Perspective- Redefining Obesity and its treatment","year":"2000"},{"issue":"1","key":"10.1016\/j.seizure.2024.08.003_bib0021","first-page":"51","article-title":"Non-alcoholic fatty liver disease and metabolic syndrome-position paper of the indian national association for the study of the liver","volume":"5","author":"Duseja","year":"2015","journal-title":"Endocr Soc India, Indian Coll Cardiol Indian Soc of Gastroenterol J Clin Exp Hepatol"},{"key":"10.1016\/j.seizure.2024.08.003_bib0022","unstructured":"The IPAQ Group (2015). Guidelines for data processing and analysis of the international physical activity questionnaire. Available at: http:\/\/www.ipaq.ki.se. Accessed on 20.04.24."},{"issue":"8","key":"10.1016\/j.seizure.2024.08.003_bib0023","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.4103\/ijo.IJO_108_18","article-title":"Therapeutic potential of valproic acid in advanced glaucoma: a pilot study","volume":"66","author":"Mahalingam","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.seizure.2024.08.003_bib0024","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchromb.2018.03.037","article-title":"Determination of plasma levetiracetam level by liquid chromatography-tandem mass spectrometry (LC-MS-MS) and its application in pharmacokinetics studies in neonates","volume":"1085","author":"Jenjirattithigarn","year":"2018","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.seizure.2024.08.003_bib0025","unstructured":"Depakene (valproic acid) capsules and oral solution. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/018081s046_18082s031lbl.pdf. Accessed on 12.05.2024."},{"key":"10.1016\/j.seizure.2024.08.003_bib0026","unstructured":"KEPPRA\u00ae (levetiracetam). Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021035s078s080,021505s021s024lbl.pdf. Accessed on 12.05.2024."},{"key":"10.1016\/j.seizure.2024.08.003_bib0027","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.seizure.2018.03.013","article-title":"The effects of valproate and topiramate use on serum insulin, leptin, neuropeptide Y and ghrelin levels in epileptic children","volume":"58","author":"\u00c7i\u00e7ek","year":"2018","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.seizure.2024.08.003_bib0028","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/jpn.JPN_152_16","article-title":"Serum insulin and leptin levels in children with epilepsy on valproate-associated obesity","volume":"12","author":"Rehman","year":"2017","journal-title":"J Pediatr Neurosci"},{"issue":"7","key":"10.1016\/j.seizure.2024.08.003_bib0029","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00381-012-1788-7","article-title":"Plasma leptin, neuropeptide Y, ghrelin, and adiponectin levels and carotid artery intima media thickness in epileptic children treated with valproate","volume":"28","author":"Tokgoz","year":"2012","journal-title":"Childs Nerv Syst"},{"issue":"2\u20133","key":"10.1016\/j.seizure.2024.08.003_bib0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.eplepsyres.2003.08.009","article-title":"Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials","volume":"56","author":"Gidal","year":"2003","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2024.08.003_bib0031","doi-asserted-by":"crossref","unstructured":"Guo H.L., Dong N., Chen F., Zeng Y.Y., Hu Y.H., Xia Y., et al. Effect of long-term valproic acid therapy on lipid profiles in paediatric patients with epilepsy: a meta-analysis. epileptic disord. 2022;24(5):822\u201330. English. doi: 10.1684\/epd.2022.1460. PMID: 35816100].","DOI":"10.1684\/epd.2022.1460"},{"key":"10.1016\/j.seizure.2024.08.003_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2019.106162","article-title":"Effect of levetiracetam monotherapy on lipid profiles and thyroid hormones in children with epilepsy: a prospective study","volume":"155","author":"Attilakos","year":"2019","journal-title":"Epilepsy Res"},{"issue":"7","key":"10.1016\/j.seizure.2024.08.003_bib0033","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1177\/0269881108091595","article-title":"Effect of valproic acid on body weight, food intake, physical activity and hormones: results of a randomized controlled trial","volume":"23","author":"Martin","year":"2009","journal-title":"J Psychopharmacol"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131124002279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131124002279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T17:11:04Z","timestamp":1759425064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131124002279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":33,"alternative-id":["S1059131124002279"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2024.08.003","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is there any concern of insulin resistance and metabolic dysfunctions with antiseizure medications? A prospective comparative study of valproate vs. levetiracetam","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2024.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}